Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Sangamo Therapeutics presents data from phase I/II EMPOWERS study of SB-318

Feb. 13, 2019

Ascendis announces phase II trial of TransCon PTH to treat hypoparathyroidism

Feb. 12, 2019

Results presented from phase I/II CHAMPIONS study of SB-913

Feb. 12, 2019

Genome editing used to create models of GM1-gangliosidosis and Morquio syndrome type B

Feb. 12, 2019

Follicum selects drug candidate for diabetes and protection of beta cells

Feb. 11, 2019

Phase III data presented for pegunigalsidase alfa in the treatment of Fabry disease

Feb. 11, 2019

Orally active GPR119 agonist demonstrates hypoglycemic effects in rats

Feb. 11, 2019

Gene therapy found effective in a mouse model of Fabry disease

Feb. 11, 2019

Improved liver-targeted AAV gene therapy has long-lasting effects in Fabry disease model

Feb. 8, 2019

Phenex-FXR presents modulators of oxysterol receptors

Feb. 8, 2019

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...